- Home
- ELLO vs PRQR Comparison
ELLO vs PRQR Comparison
Compare ELLO & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ELLO | PRQR |
|---|---|---|
| Founded | 1987 | 2012 |
| Country | Israel | Netherlands |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 255.4M | 244.1M |
| IPO Year | 1998 | 2014 |
Fundamental Metrics
Financial Performance| Metric | ELLO | PRQR |
|---|---|---|
| Price | $19.53 | $1.73 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.25 |
| AVG Volume (30 Days) | 3.2K | ★ 963.4K |
| Earning Date | 03-31-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $13.92 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.09 | $1.33 |
| 52 Week High | $30.34 | $3.10 |
Technical Indicators
Market Signals| Indicator | ELLO | PRQR |
|---|---|---|
| Relative Strength Index (RSI) | 53.59 | 50.50 |
| Support Level | $19.31 | $1.37 |
| Resistance Level | $23.43 | $1.76 |
| Average True Range (ATR) | 0.86 | 0.11 |
| MACD | 0.28 | -0.01 |
| Stochastic Oscillator | 78.88 | 30.67 |
Price Performance
Historical ComparisonAbout ELLO Ellomay Capital Ltd (Israel)
Ellomay Capital Ltd is a renewable energy company. It develops and operates renewable energy projects in Europe, the USA, and Israel, employing diverse technologies such as solar power, natural gas, pumped hydro, and waste-to-energy solutions. Geographically, the company operates in segments: Italy; Spain; USA; Netherland and Israel. It derives maximum revenue from Spain.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.